Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Q2 net loss $15.3 million, or $0.31 per share

Neutral Impact 3 of 5 earnings Written later

OnKure Therapeutics reported a second-quarter 2026 net loss of $15.3 million, or $0.31 per share, compared with $15.4 million, or $1.14 per share, a year earlier. Weighted average shares rose to 49,869,177 from 13,509,080, which accounts for most of the lower per-share loss. The company said its $176.4 million in cash, cash equivalents and marketable securities is expected to fund operations into 2029.

Key points

  • Q2 2026 net loss of $15.3 million vs. $15.4 million in Q2 2025; loss per share of $0.31 vs. $1.14
  • R&D expenses of $12.6 million, flat year over year; G&A expenses rose to $4.3 million from $3.7 million
  • Cash, cash equivalents and marketable securities of $176.4 million as of June 30, 2026, up from $59.1 million at December 31, 2025
  • IND submissions for OKI-355 and OKI-345 planned for the first half of 2027

The filing

CompanyOnKure Therapeutics, Inc. (OKUR)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:10 PM ET
Accession number0001193125-26-332809

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.